These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 33887489)

  • 1. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
    Vicente-Rabaneda EF; Atienza-Mateo B; Blanco R; Cavagna L; Ancochea J; Castañeda S; González-Gay MÁ
    Autoimmun Rev; 2021 Jun; 20(6):102830. PubMed ID: 33887489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
    Roubille C; Haraoui B
    Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
    Fernández-Díaz C; Castañeda S; Melero-González RB; Ortiz-Sanjuán F; Juan-Mas A; Carrasco-Cubero C; Casafont-Solé I; Olivé A; Rodríguez-Muguruza S; Almodóvar-González R; Castellanos-Moreira R; Rodríguez-García SC; Aguilera-Cros C; Villa I; Ordóñez-Palau S; Raya-Alvarez E; Morales-Garrido P; Ojeda-García C; Moreno-Ramos MJ; Bonilla Hernán MG; Hernández Rodríguez I; López-Corbeto M; Andreu JL; Jiménez de Aberásturi JRD; Ruibal-Escribano A; Expósito-Molinero R; Pérez-Sandoval T; López-Robles AM; Carreira-Delgado P; Mena-Vázquez N; Urruticoechea-Arana A; Peralta-Ginés C; Arboleya-Rodríguez L; Narváez García FJ; Palma-Sánchez D; Cervantes Pérez EC; Maiz-Alonso O; Alvarez-Rivas MN; Fernández-Melón J; Vela Casasempere P; Cabezas-Rodríguez I; Castellvi-Barranco I; González-Montagut C; Blanco-Madrigal J; Del Val-Del Amo N; Fito MC; Rodríguez-Gómez M; Salgado-Pérez E; García-Magallón B; Hidalgo-Calleja C; López-Sánchez R; Fernández-Aguado S; Fernández-López JC; Castro-Oreiro S; Serrano-García I; García-Valle A; Romero-Yuste S; Expósito-Pérez L; Pérez-Albadalejo L; García-Aparicio A; Quillis-Marti N; Bernal-Vidal JA; Loricera-García J; Hernández JL; González-Gay MA; Blanco R
    Rheumatology (Oxford); 2020 Dec; 59(12):3906-3916. PubMed ID: 33068439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
    Fernández-Díaz C; Atienza-Mateo B; Castañeda S; Melero-Gonzalez RB; Ortiz-SanJuan F; Loricera J; Casafont-Solé I; Rodríguez-García S; Aguilera-Cros C; Villa-Blanco I; Raya-Alvarez E; Ojeda-García C; Bonilla G; López-Robles A; Arboleya L; Narváez J; Cervantes E; Maiz O; Alvarez-Rivas MN; Cabezas I; Salgado E; Hidalgo-Calleja C; Fernández S; Fernández JC; Ferraz-Amaro I; González-Gay MA; Blanco R;
    Rheumatology (Oxford); 2021 Dec; 61(1):299-308. PubMed ID: 33779697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
    Tardella M; Di Carlo M; Carotti M; Giovagnoni A; Salaffi F
    Clin Rheumatol; 2021 Dec; 40(12):4861-4867. PubMed ID: 34313866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
    Fernández-Díaz C; Loricera J; Castañeda S; López-Mejías R; Ojeda-García C; Olivé A; Rodríguez-Muguruza S; Carreira PE; Pérez-Sandoval T; Retuerto M; Cervantes-Pérez EC; Flores-Robles BJ; Hernández-Cruz B; Urruticoechea A; Maíz-Alonso O; Arboleya L; Bonilla G; Hernández-Rodríguez Í; Palma D; Delgado C; Expósito-Molinero R; Ruibal-Escribano A; Álvarez-Rodríguez B; Blanco-Madrigal J; Bernal JA; Vela-Casasempere P; Rodríguez-Gómez M; Fito C; Ortiz-Sanjuán F; Narváez J; Moreno M; López-Corbeto M; Mena-Vázquez N; Aguilera-Cros C; Romero-Yuste S; Ordóñez S; Villa-Blanco I; Gonzélez-Vela MC; Mora-Cuesta V; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
    Semin Arthritis Rheum; 2018 Aug; 48(1):22-27. PubMed ID: 29422324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis.
    Mena-Vázquez N; Godoy-Navarrete FJ; Manrique-Arija S; Aguilar-Hurtado MC; Romero-Barco CM; Ureña-Garnica I; Espildora F; Añón-Oñate I; Pérez-Albaladejo L; Gomez-Cano C; Jimenez-Núñez FG; Padin-Martín MI; Fernández-Nebro A
    Clin Rheumatol; 2021 Jan; 40(1):133-142. PubMed ID: 32557255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.
    Atienza-Mateo B; Fernández-Díaz C; Vicente-Rabaneda EF; Melero-González RB; Ortiz-Sanjuán F; Casafont-Solé I; Rodríguez-García SC; Ferraz-Amaro I; Castañeda S; Blanco R;
    Eur J Intern Med; 2024 Jan; 119():118-124. PubMed ID: 37673775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease.
    Tardella M; Di Carlo M; Carotti M; Ceccarelli L; Giovagnoni A; Salaffi F
    Inflammopharmacology; 2022 Jun; 30(3):705-712. PubMed ID: 35462572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
    Yuan H; Cui S; Yang L; Cui J; Wang X; Ding M; Jin L; Wang Y; Chang F; Jin H; Ma J; Shi M; Liu A
    RMD Open; 2023 Oct; 9(4):. PubMed ID: 37899093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
    Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
    JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.
    Mochizuki T; Ikari K; Yano K; Sato M; Okazaki K
    Mod Rheumatol; 2019 May; 29(3):413-417. PubMed ID: 29798700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year.
    Mochizuki T; Yano K; Ikari K; Okazaki K
    Respir Investig; 2023 May; 61(3):359-363. PubMed ID: 37031622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.
    Nakashita T; Ando K; Kaneko N; Takahashi K; Motojima S
    BMJ Open; 2014 Aug; 4(8):e005615. PubMed ID: 25125479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study.
    Kang EH; Jin Y; Desai RJ; Liu J; Sparks JA; Kim SC
    Semin Arthritis Rheum; 2020 Jun; 50(3):401-408. PubMed ID: 31813561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
    Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
    Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease.
    Akiyama M; Kaneko Y
    Autoimmun Rev; 2022 May; 21(5):103056. PubMed ID: 35121155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis.
    Carrasco Cubero C; Chamizo Carmona E; Vela Casasempere P
    Reumatol Clin (Engl Ed); 2021 Nov; 17(9):504-513. PubMed ID: 34756311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.